Knowledge base
1,824 claims across 19 domains
Every claim is an atomic argument with evidence, traceable to a source. Browse by domain or search semantically.
All 1,824ai alignment 395health 320internet finance 306space development 227entertainment 169grand strategy 141collective intelligence 52mechanisms 34teleological economics 30living agents 30cultural dynamics 29critical systems 24energy 23teleohumanity 18living capital 10robotics 5manufacturing 5unknown 3technology 3
Economic downturns reduce pollution-related mortality primarily in elderly populations through air quality improvement while simultaneously increasing deaths of despair among working-age populations
A 1 percentage point increase in commuting zone unemployment rate during the 2007-2009 Great Recession was associated with a 0.5% decrease in age-adjusted mortality rate, implying a 2.3% reduction in average annual mortality for a recession-sized unemployment shock. However, this aggregate finding m
Semaglutide produces large-effect-size reductions in alcohol consumption and craving through VTA dopamine reward circuit suppression
A 9-week double-blind RCT (n=48) demonstrated that semaglutide produces clinically significant reductions in alcohol consumption through the same VTA dopamine reward circuit mechanism that drives its metabolic effects. The trial showed dose-response escalation: small-to-medium effects at 0.25mg (wee
WHO's December 2025 GLP-1 guideline marks the first global endorsement of pharmacological obesity treatment but its conditional status signals inadequate health system readiness and unresolved equity concerns
On December 1, 2025, WHO issued its first-ever global guideline on GLP-1 medicines for obesity treatment, covering liraglutide, semaglutide, and tirzepatide. Critically, the recommendation is conditional rather than strong. WHO explicitly states the conditional status is driven by: (1) limited data
The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment
The study identifies the precise neural circuit mediating hedonic eating: periLC_VGLUT2 → VTA_VGAT ⊣ VTA_DA → NAc dopamine. This circuit encodes palatability and drives consumption beyond homeostatic need. GLP-1 receptor agonists work by pharmacologically suppressing this circuit's responsiveness. T
GLP-1 appetite suppression creates a protein deficiency pathway that causes muscle loss, making resistance training mechanistically necessary rather than complementary
GLP-1 receptor agonists produce greater short-term weight loss than exercise alone, but this pharmacological advantage creates a specific risk: appetite suppression and reduced gastric emptying limit protein intake and nutrient absorption necessary for muscle preservation. The review identifies resi
Hospital-physician consolidation consistently increases prices without improving quality as price effects are confirmed while quality evidence is mixed-to-negative across four years of literature
The GAO reviewed peer-reviewed studies published between January 2021 and July 2025, finding that hospital-physician consolidation produces consistent price increases but quality outcomes that are 'same or lower' after consolidation. The report states that 'studies show consolidation can increase sp
Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery
Researchers at Janelia Research Campus identified the specific neural circuit controlling hedonic eating: peri-locus ceruleus → ventral tegmental area dopamine neurons → nucleus accumbens. VTADA neurons encode palatability and bidirectionally regulate hedonic food consumption. Critically, semaglutid
GLP-1 obesity coverage creates acute payer fiscal crisis with employer plans experiencing >10x PMPM cost increases in 2023-2024 and major insurers reporting operating losses driven primarily by GLP-1 expenditures
ICER's April 2025 white paper documents that self-insured employers offering GLP-1 obesity coverage experienced >10x increase in per-member, per-month (PMPM) costs from January 2023 to December 2024. Blue Cross Blue Shield of Massachusetts ended 2024 with a $400 million operating loss, with GLP-1 dr
WHO's GLP-1 guideline rates behavioral interventions as optional supplements with only low-certainty evidence that they enhance pharmacological outcomes
WHO's December 2025 GLP-1 guideline includes a secondary recommendation that intensive behavioral interventions (structured healthy diet + physical activity + professional support) 'may be offered' to adults taking GLP-1s for obesity. Critically, this recommendation is based on 'low-certainty eviden
AI micro-learning loop creates durable upskilling through review-confirm-override cycle at point of care
Oettl et al. propose that AI creates a 'micro-learning at point of care' mechanism where clinicians must 'review, confirm or override' AI recommendations, which they argue reinforces diagnostic reasoning rather than causing deskilling. This is the theoretical counter-mechanism to the deskilling thes
Never-skilling affects trainees while deskilling affects experienced physicians creating distinct population risks with different intervention requirements
Oettl et al. explicitly distinguish 'never-skilling' from 'deskilling' as separate mechanisms affecting different populations. Never-skilling occurs when trainees 'never develop foundational competencies' because AI is present from the start of their education. Deskilling occurs when experienced phy
State Medicaid budget pressure is actively reversing GLP-1 obesity coverage gains with California and three other states eliminating coverage in 2025-2026
As of January 2026, only 13 states (26% of state programs) cover GLP-1s for obesity under fee-for-service Medicaid, but critically, four states have actively eliminated existing coverage due to budget pressure: California, New Hampshire, Pennsylvania, and South Carolina. California's Medi-Cal projec
AI-defined case routing prevents trainees from developing threshold-setting skills required for independent practice
The paper notes that 'only human experts can revise the thresholds for case prioritization'—but this statement reveals a deeper problem: AI defines what humans see in the first place. When trainees are trained under an AI threshold system, they encounter only the cases the AI routes to them. This pr
The Medicare GLP-1 Bridge program's Low-Income Subsidy exclusion structurally denies the lowest-income Medicare beneficiaries access to GLP-1 obesity coverage despite nominal eligibility
The Medicare GLP-1 Bridge program (July-December 2026) covers Wegovy and Zepbound at a fixed $50 copayment for eligible Part D beneficiaries. However, the program contains a critical structural flaw: Low-Income Subsidy (LIS) cost-sharing subsidies will not apply to GLP-1 prescriptions filled under t
Never-skilling is mechanistically distinct from deskilling because it affects trainees who lack baseline competency rather than experienced physicians losing existing skills
Oettl et al. explicitly distinguish 'never-skilling' from deskilling as separate mechanisms with different populations and dynamics. Deskilling affects experienced physicians who have baseline competency and lose it through AI reliance. Never-skilling affects trainees who never develop foundational
AI-integrated cervical cytology screening reduces trainee exposure to routine cases creating never-skilling risk for foundational pattern recognition skills
AI automation in cervical cytology screening targets 'routine processes, such as initial screenings and pattern recognition in straightforward cases' for efficiency gains. However, these routine cases are precisely where trainees develop foundational pattern recognition skills. As AI handles large v
Federal GLP-1 expansion programs reproduce the access hierarchy at the program design level, not just through market dynamics
The Medicare GLP-1 Bridge program demonstrates that the GLP-1 access inversion operates at the program design level, not just the market level. While the program was designed to 'expand access' to GLP-1 obesity medications, its legal architecture—required because Medicare is statutorily prohibited f
Medicaid-accepting facilities are 25 percent less likely to offer telehealth services, reproducing in-person access disparities in digital modalities
The JMIR 2024 study found that facilities accepting Medicaid were approximately 25 percent less likely to offer telehealth services compared to non-Medicaid facilities. This creates a structural inversion where populations with the greatest need for telehealth access (Medicaid enrollees, who face tr
Audio-only telehealth is the equity-relevant modality because it over-indexes on populations that video-based telehealth systematically underserves
Among telehealth modalities, audio-only demonstrates a distinct equity profile. Medicare beneficiaries who are older, racial/ethnic minorities, dual-enrolled, rural, or have low broadband access are significantly more likely to use audio-only than video-based telehealth. This pattern inverts the typ
WHO endorsed GLP-1s for obesity treatment in December 2025 while USPSTF maintains its 2018 recommendation excluding pharmacotherapy creating the largest international-US preventive coverage policy gap in modern history
On December 1, 2025, WHO issued a formal clinical guideline recommending GLP-1 receptor agonists (liraglutide, semaglutide) and GIP/GLP-1 dual agonists (tirzepatide) as a long-term treatment option for obesity in adults. This was designated as a 'conditional recommendation, moderate-certainty eviden
Optional-use AI deployment where clinicians form independent judgment before consulting AI may structurally prevent automation bias and deskilling mechanisms observed in mandatory-use systems
The PRAIM study deployed AI mammography screening across 12 German sites with 463,094 women and 119 radiologists using an optional-use design: radiologists made their own primary read first, then voluntarily chose whether to consult AI. This design achieved a 17.6% increase in cancer detection (6.7
After societies cross a material wealth threshold the primary determinant of health shifts from absolute deprivation to relative social deprivation
Richard Wilkinson identified a phase transition in the determinants of population health. Below a critical threshold of material wealth, health outcomes track GDP closely — richer societies are dramatically healthier. Above that threshold, the relationship breaks down. Among OECD countries, the long
Cytology lab consolidation creates never-skilling pathway through 80 percent training volume destruction
Following UK cervical screening consolidation with AI-assisted reading, case volumes reduced 80-85% while labs consolidated from 45 to 8 centers. The authors identify this as having 'major implications for training capacity.' This represents a distinct mechanism from individual cognitive deskilling:
No peer-reviewed evidence of durable physician upskilling from AI exposure as of mid-2026
The Heudel et al. scoping review examined literature through August 2025 across colonoscopy, radiology, pathology, and cytology. Authors conclude: 'empirical studies consistently demonstrate that AI can inadvertently impair physicians' performance.' The review found NO opposing evidence — no studies
Culturally adapted digital mental health interventions achieve double the effect size for racial/ethnic minorities compared to standard apps
The JMIR 2024 meta-analysis found that culturally adapted digital mental health interventions achieve an effect size of g=0.90 for racial/ethnic minorities, compared to g=0.43 for standard apps—a 2.1x improvement. This suggests that the widely documented efficacy gap for digital mental health in min
Page 6 of 13